Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis

Clinical Rheumatology

Volumn 35, Issue 2, 2016, Pages 417-425

  Ruan, Qiaoling ^a   Zhang, Shu ^a   Ai, Jingwen ^a   Shao, Lingyun ^a   Zhang, Wenhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Interferon gamma release assay; Latent tuberculosis; Rheumatic disease; Tuberculin skin test

Indexed keywords

STEROID; BCG VACCINE;

ARTICLE; BCG VACCINATION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; META ANALYSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; RHEUMATIC DISEASE; STEROID THERAPY; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; BIOLOGICAL THERAPY; COMPLICATION; IMMUNOSUPPRESSIVE TREATMENT; RHEUMATIC DISEASES;

BCG VACCINE; BIOLOGICAL THERAPY; HUMANS; IMMUNOSUPPRESSION; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; RHEUMATIC DISEASES; TUBERCULIN TEST;

EID: 84958183103     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2817-6     Document Type: Article

References (41)

1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104. doi:10.1056/NEJMoa011110
2. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3(3):148–155. doi:10.1016/S1473-3099(03)00545-0
3. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Group B (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48(8):2122–2127. doi:10.1002/art.11137
4. Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50(2):372–379. doi:10.1002/art.20009
5. Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ (2014) Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). doi:10.1093/rheumatology/keu172
6. Stewart GR, Robertson BD, Young DB (2003) Tuberculosis: a problem with persistence. Nat Rev Microbiol 1(2):97–105. doi:10.1038/nrmicro749
7. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol (Baltimore, Md: 1950) 168(9):4620–4627. doi:10.4049/jimmunol.168.9.4620
8. Tufariello JM, Chan J, Flynn JL (2003) Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 3(9):578–590. doi:10.1016/S1473-3099(03)00741-2
9. Lalvani A, Millington KA (2008) Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 8(2):147–152. doi:10.1016/j.autrev.2008.07.011
10. British Thoracic Society Standards of Care C (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60(10):800–805. doi:10.1136/thx.2005.046797
11. Centers for Disease C, Prevention (2004) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha–California, 2002–2003. MMWR Morb Mortal Wkly Rep 53(30):683–686
12. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, Carreno L, Figueroa M, Group B (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52(6):1766–1772. doi:10.1002/art.21043
13. Mariette X, Salmon D (2003) French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 62(8):791. doi:10.1136/ard.62.8.791
14. Pouchot J, Grasland A, Collet C, Coste J, Esdaile JM, Vinceneux P (1997) Reliability of tuberculin skin test measurement. Ann Intern Med 126(3):210–214. doi:10.7326/0003-4819-126-3199702010-00005
15. Menzies D (1999) Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 159(1):15–21. doi:10.1164/ajrccm.159.1.9801120
16. Pai M, Zwerling A, Menzies D (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149(3):177–184. doi:10.7326/0003-4819-149-3-200808050-00241
17. Mori T (2009) Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. J Infect Chemother Off J Jpn Soc Chemother 15(3):143–155. doi:10.1007/s10156-009-0686-8
18. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. doi:10.1371/journal.pmed.1000097
19. Schueler S, Schuetz GM, Dewey M (2012) The revised QUADAS-2 tool. Ann Intern Med 156(4):323. doi:10.7326/0003-4819-156-4-201202210-00018, author reply 323–324
20. Shahidi N, Fu YT, Qian H, Bressler B (2012) Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 18(11):2034–2042. doi:10.1002/ibd.22901
21. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, Marston BJ, Huang L, Hopewell PC, Pai M (2011) Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 56(3):230–238. doi:10.1097/QAI.0b013e31820b07ab
22. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. doi:10.1002/sim.1186
23. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, Perich R, Sanchez-Torres A, Pastor C, Sanchez-Schwartz C, Medina M, Gamboa R, Ugarte M (2008) Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 35(5):776–781
24. Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, Thomsen VO, Jensen DV, Koch A, Wohlfahrt J, Ravn P (2009) Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 36(9):1876–1884. doi:10.3899/jrheum.081292
25. Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, Codd MB, Dodd J, Veale D, Fitzgerald O, Bresnihan B (2010) Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis. Ann Rheum Dis 69(1):181–185. doi:10.1136/ard.2008.101857
26. Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, Hadziyannis E (2011) Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol CVI 18(12):2102–2108. doi:10.1128/CVI. 05299-11
27. Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM, Kang ES, Koh WJ (2011) Interferon-gamma release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 30(12):1535–1541. doi:10.1007/s10067-011-1771-9
28. Belard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-Lassen I, Ravn P (2011) Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 17(11):2340–2349. doi:10.1002/ibd.21605
29. Maeda T, Banno S, Maeda S, Naniwa T, Hayami Y, Watanabe M, Sato S, Ueda R (2011) Comparison of QuantiFERON-TB Gold and the tuberculin skin test for detecting previous tuberculosis infection evaluated by chest CT findings in Japanese rheumatoid arthritis patients. J Infect Chemother Off J Jpn Soc Chemother 17(6):842–848. doi:10.1007/s10156-011-0250-1
30. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL (2012) Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFalpha inhibitors: the utility of IFN gamma assay. Ann Rheum Dis 71(2):231–237. doi:10.1136/annrheumdis-2011-200489
31. Minguez S, Latorre I, Mateo L, Lacoma A, Diaz J, Olive A, Dominguez J (2012) Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol 31(5):785–794. doi:10.1007/s10067-012-1938-z
32. Mariette X, Baron G, Tubach F, Liote F, Combe B, Miceli-Richard C, Flipo RM, Goupille P, Allez M, Salmon D, Emilie D, Carcelain G, Ravaud P (2012) Influence of replacing tuberculin skin test with ex vivo interferon gamma release assays on decision to administer prophylactic antituberculosis antibiotics before anti-TNF therapy. Ann Rheum Dis 71(11):1783–1790. doi:10.1136/annrheumdis-2011-200408
33. Klein M, Jarosova K, Forejtova S, Becvar R, Sedova L, Pavelka K, Simkova G, Svobodova R, Hviscova K, Mann H, Putova I, Vencovsky J (2013) Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents. Clin Exp Rheumatol 31(1):111–117
34. Kwakernaak AJ, Houtman PM, Weel JF, Spoorenberg JP, Jansen TL (2011) A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor alpha inhibitor. Clin Rheumatol 30(4):505–510. doi:10.1007/s10067-010-1550-z
35. Richeldi L, Losi M, D’Amico R, Luppi M, Ferrari A, Mussini C, Codeluppi M, Cocchi S, Prati F, Paci V, Meacci M, Meccugni B, Rumpianesi F, Roversi P, Cerri S, Luppi F, Ferrara G, Latorre I, Gerunda GE, Torelli G, Esposito R, Fabbri LM (2009) Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 136(1):198–204. doi:10.1378/chest. 08-2575
36. Beffa P, Zellweger A, Janssens JP, Wrighton-Smith P, Zellweger JP (2008) Indeterminate test results of T-SPOT.TB performed under routine field conditions. Eur Respir J 31(4):842–846. doi:10.1183/09031936.00117207
37. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, Pastor C, Harrison J, Sanchez-Schwartz C (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64(9):1360–1361. doi:10.1136/ard.2004.029041
38. Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, Pai M (2011) Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immune-mediated inflammatory disorders. Curr Opin Rheumatol 23(4):377–384. doi:10.1097/BOR.0b013e3283474d62
39. CDC (2010) Updated guidelines for using interferon gamma release assays to detect Mycobacterium-United States, 2010. Morb Mortal Wkly Rep 59
40. ECDC (2011) Use of interferon-gamma release assays in support of TB diagnosis. 2011
41. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Scholvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C (2010) The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 36(5):1185–1206. doi:10.1183/09031936.00028510